肾去神经术通过抑制肾素-血管紧张素系统预防心力衰竭进展
该研究在正常血压的猪心肌梗死后射血分数降低心力衰竭(HFrEF)模型中,评估射频肾去神经术(RF-RDN)的疗效。结果显示RF-RDN降低肾脏去甲肾上腺素含量及循环血管紧张素I和II,升高B型利钠肽,减小左室收缩末期容积,持续改善射血分数和纵向应变,减轻纤维化并改善冠状动脉血管功能,从而阻止HFrEF进展。
要点
- RF-RDN降低肾脏去甲肾上腺素及循环血管紧张素I和II,抑制肾素-血管紧张素系统。
- RF-RDN减小左室收缩末期容积,持续改善射血分数和纵向应变。
- RF-RDN减轻左室纤维化并改善冠状动脉对血管扩张剂的反应。
核心结论
- RF-RDN通过降低肾交感活性、抑制肾素-血管紧张素系统、升高循环B型利钠肽、减轻左室纤维化并改善左室性能和冠状动脉血管功能,协同阻止心肌梗死后HFrEF进展。
研究设计与样本
- 研究采用尤卡坦小型猪,经左前降支冠状动脉球囊闭塞75分钟诱导心肌梗死再灌注,随访18周。
- 以左室射血分数<40%定义HFrEF,符合入选标准的动物在心肌梗死后6周随机接受双侧RF-RDN(n=10)或假手术(n=11)。
主要发现
- RF-RDN显著降低肾脏去甲肾上腺素含量及循环血管紧张素I和II。
- RF-RDN显著升高循环B型利钠肽水平。
- 与假手术组相比,RF-RDN组左室收缩末期容积显著减小,左室射血分数显著且持续改善。
- RF-RDN改善左室纵向应变,减轻左室纤维化,并改善冠状动脉对血管扩张剂的反应。
关键数值与推荐
- HFrEF定义为左室射血分数<40%。
- 心肌梗死再灌注后6周进行随机分组,随访至18周。
临床怎么用
- 在心肌梗死后HFrEF模型中,RF-RDN可能作为抑制肾素-血管紧张素系统、改善左室重构和冠状动脉功能的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previously, we have shown that radiofrequency (RF) renal denervation (RDN) reduces myocardial infarct size in a rat model of acute myocardial infarction (MI) and improves left ventricular (LV) function and vascular reactivity in the setting of heart failure following MI. OBJECTIVES: The authors investigated the therapeutic efficacy of RF-RDN in a clinically relevant normotensive swine model of heart failure with reduced ejection fraction (HFrEF). METHODS: Yucatan miniswine underwent 75 min of left anterior descending coronary artery balloon occlusion to induce MI followed by reperfusion (R) for 18 weeks. Cardiac function was assessed pre- and post-MI/R by transthoracic echocardiography and every 3 weeks for 18 weeks. HFrEF was classified by an LV ejection fraction <40%. Animals who met inclusion criteria were randomized to receive bilateral RF-RDN (n = 10) treatment or sham-RDN (n = 11) at 6 weeks post-MI/R using an RF-RDN catheter. RESULTS: RF-RDN therapy resulted in significant reductions in renal norepinephrine content and circulating angiotensin I and II. RF-RDN significantly increased circulating B-type natriuretic peptide levels. Following RF-RDN, LV end-systolic volume was significantly reduced when compared with sham-treated animals, leading to a marked and sustained improvement in LV ejection fraction. Furthermore, RF-RDN improved LV longitudinal strain. Simultaneously, RF-RDN reduced LV fibrosis and improved coronary artery responses to vasodilators. CONCLUSIONS: RF-RDN provides a novel therapeutic strategy to reduce renal sympathetic activity, inhibit the renin-angiotensin system, increase circulating B-type natriuretic peptide levels, attenuate LV fibrosis, and improve left ventricular performance and coronary vascular function. These cardioprotective mechanisms synergize to halt the progression of HFrEF following MI/R in a clinically relevant model system.
引用
- Sharp TE, Polhemus DJ, Li Z, et al. Renal Denervation Prevents Heart Failure Progression Via Inhibition of the Renin-Angiotensin System. J Am Coll Cardiol. 2018. PMID: 30466519. doi:10.1016/j.jacc.2018.08.2186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。